Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
CVS Group flags lower full-year sales growth
(Sharecast News) - Listed veterinary service provider CVS Group said in an update on Thursday that it achieved growth of around 10% in full-year revenue for continuing operations, with like-for-like sales increasing 2.9%, compared to 7.3% in the 2023 financial year. The AIM-traded firm said its revenue growth for the 12 months ended 30 June was impacted by a cyber incident in April, which prompted an accelerated cloud migration for the group's UK companion animal practices, alongside softer demand which it put down to publicity around the veterinary sector and ongoing cost-of-living pressures.
Adjusted for the cyber incident, underlying like-for-like sales growth would have been around 4.1%.
The group said it expected to report 2024 adjusted EBITDA of around £127m, with an adjusted EBITDA margin at the lower end of the stated range of 19% to 23%.
CVS said it continued to expand its presence in Australia, completing 22 practice acquisitions at 28 practice sites for a total initial consideration of AUD 157.6m (£82.4m) in the financial year, with one additional acquisition post-year-end.
Leverage was anticipated to be around 1.5x as of 30 June, up from 0.73x a year ago, while maintaining significant headroom with over £165m in undrawn bank facilities.
Membership in the group's Healthy Pet Club preventive healthcare scheme increased by 14,000 to 503,000 members.
Notably, CVS paused its UK acquisition activity pending the outcome of the Competition and Markets Authority (CMA) market investigation.
The group said it was actively supporting the CMA's investigation, which was expected to conclude by November next year.
CVS said the cyber incident detected in April involved unauthorised access to some IT servers.
The incident, now fully resolved, was expected to incur exceptional costs of £4m to £5m.
CVS said the event, alongside the subsequent IT infrastructure modernisation, adversely impacted trading by about £7m in the final quarter.
Strategically, CVS divested its loss-making operations in the Netherlands and the Republic of Ireland in May, resulting in a non-cash write-down in its 2024 accounts.
The group said it was continuing to invest in practice facilities, clinical equipment, and technology, with total capital expenditure of around £42m in 2024.
Looking ahead, CVS reaffirmed its capital allocation strategy, focusing on operational cash conversion of around 70%, investing over £50m annually in overseas acquisitions, and maintaining leverage below 2.0x.
The group said it anticipated focusing its 2025 capital allocation towards opportunities in Australia, building on its existing platform to drive sustainable growth.
Board changes included the appointment of Paul Higgs, chief veterinary officer, as an executive director, and Joanne Shaw as the new chair of the audit committee, succeeding David Wilton.
"On behalf of the board I am delighted to welcome Paul Higgs," said chair David Wilton.
"Paul's commitment to advancing clinical quality, his passion for the development of the group's clinicians and his engagement with the veterinary professional bodies will support the board and the wider group in delivering its purpose to give the best possible care to animals."
Despite short-term headwinds, CVS said it was still optimistic about its long-term prospects, supported by a growing pet population, increasing pet life expectancy, and advancements in clinical care.
The firm said it expected to announce its 2024 preliminary results on 26 September.
At 1148 BST, shares in CVS Group were up 0.57% at 1,056p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.